According to investment bank UBS, nearly 18 million Americans are expected to be taking GLP-1 drugs by 2029, indicating a major shift in obesity treatment.
The National Health and Nutrition Examination Survey shows a decline in obesity rates, with 40.3% of adults classified as obese, down from a peak of 41.9%.
As the popularity of GLP-1 drugs increases, traditional dieting methods and treatments like bariatric surgery are declining, causing significant disruptions in the obesity management landscape.
Challenges surrounding the accessibility of GLP-1 drugs remain, with prices ranging from $936 to $1,349 per month and widespread shortages affecting prescription fulfillment.
Collection
[
|
...
]